GNR-086 (canakinumab biosimilar)
/ Generium
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 26, 2024
CAN-AOSD-III: An Efficacy and Safety Study of GNR-086 (canakinumab Biosimilar) and Ilaris® in Patients with Adult-onset Still's Disease
(clinicaltrials.gov)
- P3 | N=148 | Recruiting | Sponsor: AO GENERIUM | Active, not recruiting ➔ Recruiting
Enrollment open • Immunology
1 to 1
Of
1
Go to page
1